Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1584151 | 1.00 | NMT1 (0.39) | NMT1FFAR1HRH3CHRNB2CHRNA7 | |
| SCHEMBL27037984 | 0.90 | HRH3 (0.42) | NMT1FFAR1HRH3DPP4FAP | |
| SCHEMBL1584388 | 0.84 | FFAR1 (0.41) | NMT1FFAR1PPARG | |
| SCHEMBL1584386 | 0.84 | FFAR1 (0.41) | NMT1FFAR1PPARG | |
| SCHEMBL12707818 | 0.84 | FFAR1 (0.46) | NMT1FFAR1ARPPARG | |
| SCHEMBL1604449 | 0.80 | FFAR1 (0.51) | FFAR1HRH3PPARG | |
| SCHEMBL1604447 | 0.80 | FFAR1 (0.51) | FFAR1HRH3PPARG | |
| SCHEMBL1584659 | 0.80 | FFAR1 (0.44) | FFAR1PPARG | |
| SCHEMBL1584660 | 0.80 | FFAR1 (0.44) | FFAR1PPARG | |
| SCHEMBL1584832 | 0.80 | FFAR1 (0.43) | NMT1FFAR1CHRNB2ARPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486005-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8288404-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2486005-A1 | PYRROLIDINE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044073-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR27 | NMT1 1491/4885FFAR1 37/4885HRH3 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.